Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Financial Officer | August 31, 2026 | September 01, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 31, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,024 |
Ending reported balance
After 2026-08-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 57,187 · Balance 176,798 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. Row 2 · 2026-08-31 · Sale · Disposed 23,072 · Balance 153,726 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-31 · Sale · Disposed 11,514 · Balance 142,212 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-31 · Sale · Disposed 28,188 · Balance 114,024 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 3,813 |
Reported balance
After 2026-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-31 · Exercise / conversion · Disposed 57,187 · Balance 3,813 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENESEE & WYOMING INC
Report date December 30, 2019 · Filed December 30, 2019
Section 16 reporting ended · disclosed 2019-12-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-30 transaction · row 1
1 source rowRow 1 · 2019-12-30 · Disposition to issuer · Disposed 11,824 · Balance 0 F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration.
F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2018 Filed Sep 6, 2018 20:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-18-055584 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,744 Underlying: Common Stock · 3,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 20:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,000 | $6.88 | $20,640.00 |
DisclosureSEC source: 0001104659-18-055584 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 16:21 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 229 | $80.48 | $18,429.92 |
DisclosureSEC source: 0001209191-18-041049 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,324 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| May 23, 2018 Filed May 25, 2018 13:55 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 1,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033428 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,095 F1 · shares: This restricted stock award was granted under the Fourth Amended and Restated 2004 Omnibus Incentive Plan of Genesee & Wyoming Inc. (the "Company"). The shares subject to the restricted stock award will vest in two equal installments on the dates of the next two annual meetings of the Company. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 17:00 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 298 | $70.14 | $20,901.72 |
DisclosureSEC source: 0001209191-18-023116 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,794 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 61,000 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001104659-18-010370 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 61,000 shares Expires 2028-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 16:20 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 361 | $78.72 | $28,417.92 |
DisclosureSEC source: 0001209191-18-000873 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,496 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 16:27 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 250 | $73.53 | $18,382.50 |
DisclosureSEC source: 0001209191-17-055102 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,135 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:20 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 271 | $67.83 | $18,381.93 |
DisclosureSEC source: 0001209191-17-043323 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,885 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| May 24, 2017 Filed May 25, 2017 16:39 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035433 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,614 F1 · shares: This restricted stock award was granted under the Third Amended and Restated 2004 Omnibus Incentive Plan of Genesee & Wyoming Inc. (the "Company"). The shares subject to the restricted stock award will vest in three equal installments on the dates of the next three annual meetings of the Company. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 16:20 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 270 | $68.10 | $18,387.00 |
DisclosureSEC source: 0001209191-17-024755 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,225 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 16:19 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 354 | $69.59 | $24,634.86 |
DisclosureSEC source: 0001209191-17-000870 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,955 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:24 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 307 | $68.10 | $20,906.70 |
DisclosureSEC source: 0001209191-16-144501 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,601 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Third Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.